title: Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.
abstract: Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum- based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy.
authors.affiliation: Division of Oncology-Hematology, Department of Internal Medicine, School of Medicine, Gyeongsang National University, 79 Gangnam-ro, Jinju 660-702, Korea. brightree@lycos.co.kr
authors.forename: Yun-Hong
authors.initials: YH
authors.lastname: Cheon
authors.forename: Moon Jin
authors.initials: MJ
authors.lastname: Kim
authors.forename: Min Gyu
authors.initials: MG
authors.lastname: Kang
authors.forename: Hee Jin
authors.initials: HJ
authors.lastname: Kim
authors.forename: Sang Su
authors.initials: SS
authors.lastname: Lee
authors.forename: Cha Young
authors.initials: CY
authors.lastname: Kim
authors.forename: Dae-Hong
authors.initials: DH
authors.lastname: Jeon
authors.forename: Yu Eun
authors.initials: YE
authors.lastname: Kim
authors.forename: Gyeong-Won
authors.initials: GW
authors.lastname: Lee
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D007412:Intestinal Fistula / Q000139:chemically induced* / Q000150:complications / Q000000981:diagnostic imaging / Q000601:surgery; D007416:Intestinal Perforation / Q000139:chemically induced* / Q000150:complications / Q000000981:diagnostic imaging / Q000601:surgery; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D011859:Radiography; D012810:Sigmoid Diseases / Q000139:chemically induced* / Q000150:complications / Q000000981:diagnostic imaging / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride